- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital Care Center - North Haven6 Devine Street, Fl 1North Haven, CT 06473
Jill Lacy, MD
Biography
Jill Lacy, MD, is a medical oncologist who specializes in gastrointestinal (GI) cancers, including pancreatic and colorectal cancers.
Dr. Lacy works with patients using chemotherapy (which destroys cancer cells with chemicals), immunotherapy (which uses drugs to harness the immune system to fight cancer), and targeted therapy (which targets proteins that control how cancer cells behave).
An active researcher, Dr. Lacy has published studies examining the outcomes of targeted therapy and GI cancers, including potentially harmful side effects, and different treatments for metastatic pancreatic cancer.
In 2020, Dr. Lacy was one of five physicians receiving a Yale Medicine Distinguished Clinical Career Award. The award highlights doctors whose careers demonstrate significant accomplishments and dedication.
Titles
- Professor of Medicine (Medical Oncology)
Education & Training
- FellowYale University School of Medicine (1985)
- ResidentYale University School of Medicine (1982)
- MDYale University (1978)
Additional Information
- Fellow: American Society of Clinical Oncology (2021)
- America's Top Doctors (digital guide): 2016, 2017, 2018, 2019, 2020, 2021: Castle Connolly (2021)
- Exceptional Women In Medicine: Castle Connolly (2019)
- Top Doctors for Cancer, Newsweek Magazine July 2015: (2015)
- Castle Connolly America's Top Doctors for Cancer (digital guide): 2016, 2017, 2018, 2019, 2020, 2021: (2015)
- Member, ASCO Oncology Training Programs Committee, 2007-2010: American Society of Clinical Oncology
- Member, ASCO Diversity in Oncology Initiative Advisory and Review Comm, 2008-present: American Society of Clinical Oncology
- Chairwoman, ASCO Diversity in Oncology Initiative Advisory and Review Comm, 2011, 2012: American Society of Clinical Oncology
- New York Magazine Top Doctor (Medical Oncology), 2006-2008 :
- AB of Internal Medicine, Medical Oncology (1993, recertified: 2015)
- AB of Internal Medicine, Internal Medicine (1982)
- Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ)Cecchini M, Chao J, Shyr Y, Cleary J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Hsu C, Stein S, Thumar J, Kortmansky J, Kunstman J, LoRusso P, Ivy P, Lacy J. Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ) Cancer Research 2022, 82: ct170-ct170. DOI: 10.1158/1538-7445.am2022-ct170.
- Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Cecchini M, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Eder J, Zhang J, Ross J. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. Journal Of Clinical Oncology 2022, 40: 3535-3535. DOI: 10.1200/jco.2022.40.16_suppl.3535.
- Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).Philip P, Bahary N, Mahipal A, Kasi A, Rocha Lima C, Alistar A, Oberstein P, Golan T, Sahai V, Metges J, Lacy J, Fountzilas C, Lopez C, Ducreux M, Hammel P, Salem M, Bajor D, Benson A, Buyse M, Van Cutsem E. Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500). Journal Of Clinical Oncology 2022, 40: 4023-4023. DOI: 10.1200/jco.2022.40.16_suppl.4023.
- Wang JD, Sebastian C, Walther Z, Suresh T, Lacy J, Zhang X, Jain D. An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach. Archives Of Pathology & Laboratory Medicine 2022 PMID: 35512224, DOI: 10.5858/arpa.2021-0457-oa.
- Grant MJ, Finberg KE, Walther Z, Stein SM, Lacy J, Eder JP, Goldberg SB. Yale Precision Medicine Tumor Board: reawakening the guardian of the genome The Lancet Oncology 2022, 23: 337-338. PMID: 35240081, DOI: 10.1016/s1470-2045(22)00037-7.
- Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2022, 20: 167-192. PMID: 35130500, DOI: 10.6004/jnccn.2022.0008.
- Patel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, DOI: 10.21037/jgo-21-202.
- Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal CancerPeters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
- Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients.Uhlig J, Stein S, Lacy J, Cecchini M, Kim K. Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients. Journal Of Clinical Oncology 2021, 39: 462-462. DOI: 10.1200/jco.2021.39.3_suppl.462.
- 259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRCManji G, Bahary N, Chung V, Dalenc F, Ducreux M, Gomez-Roca C, Im S, Kortmansky J, Lacy J, Segal N, Tredan O, Cirovic O, DuPree K, Lenain C, Lu D, Robert L, Xu J, Zhang X, Kim S. 259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC 2020, a157-a158. DOI: 10.1136/jitc-2020-sitc2020.0259.
- Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database AnalysisMiccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.
- The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic CancerMiccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.
- Microsatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database.Uhlig J, Cecchini M, Stein S, Lacy J, Kim K. Microsatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: e16052-e16052. DOI: 10.1200/jco.2020.38.15_suppl.e16052.
- Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).Ko A, Lee J, ALSINA M, Ajani J, Bang Y, Chung H, Lacy J, Lopez C, Oh D, O'Reilly E, Siveke J, Allen S, Al-Sakaff N, Barak H, Lau J, Li S, Retiere A, Shemesh C, Zhang X, Kim K. Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). Journal Of Clinical Oncology 2020, 38: 4540-4540. DOI: 10.1200/jco.2020.38.15_suppl.4540.
- Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study.Patel T, Miccio J, Srikumar T, Prsic E, Adelson K, Kozhevnikov D, Patel K, Lacy J, Cecchini M. Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study. Journal Of Clinical Oncology 2020, 38: 770-770. DOI: 10.1200/jco.2020.38.4_suppl.770.
- Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System.Patel T, Srikumar T, Miccio J, Lacy J, Stein S, Kortmansky J, Staugaard C, Gambaccini M, Axtmayer A, Cecchini M. Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System. Journal Of Clinical Oncology 2020, 38: 769-769. DOI: 10.1200/jco.2020.38.4_suppl.769.
- Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database.Uhlig J, Nie J, Stein S, Cecchini M, Lacy J, Kim H. Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 609-609. DOI: 10.1200/jco.2020.38.4_suppl.609.
- HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).Tempero M, Van Cutsem E, Sigal D, Oh D, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar A, Bates S, Li C, De La Fouchardiere C, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Bullock A. HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). Journal Of Clinical Oncology 2020, 38: 638-638. DOI: 10.1200/jco.2020.38.4_suppl.638.
- Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).Oh D, Ajani J, Bang Y, Chung H, Lacy J, Lee J, Macarulla T, Manji G, O'Reilly E, Allen S, Al-Sakaff N, Barak H, Patel J, Pintoffl J, Shemesh C, Zhang W, Zhang X, Chau I. Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). Journal Of Clinical Oncology 2020, 38: 712-712. DOI: 10.1200/jco.2020.38.4_suppl.712.
- Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysisBuettner S, Janssen Q, Suker M, Beumer B, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali M, Besselink M, Boone B, Chau I, Clarke S, Dillhoff M, El-Rayes B, Frakes J, Grose D, Hosein P, Jamieson N, Javed A, Khan K, Kim K, Kim S, Kim S, Ko A, Lacy J, Margonis G, McCarter M, McKay C, Mellon E, Moorcraft S. Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis Hepato Pancreato Biliary 2020, 22: s327. DOI: 10.1016/j.hpb.2020.04.310.
- 1188PD Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysisCatenacci D, Park H, Uronis H, Kang Y, Ng M, Enzinger P, Lee K, Lim K, Gold P, Lacy J, Park S, Huber K, Wynter-Horton A, Nordstrom J, Wu T, Wigginton J, Baughman J, Rosales M, Davidson-Moncada J, Bang Y. 1188PD Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis Annals Of Oncology 2019, 30: v484-v485. DOI: 10.1093/annonc/mdz253.014.
- KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US.Uhlig J, Stein S, Lacy J, Kim H. KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US. Journal Of Clinical Oncology 2019, 37: e15138-e15138. DOI: 10.1200/jco.2019.37.15_suppl.e15138.
- OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative RadiationMiccio J, Cecchini M, Pahade J, Lacy J, Salem R, Johnson S, Blakaj A, Stein S, Kortmansky J, Johung K. OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative Radiation International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e10-e11. DOI: 10.1016/s0360-3016(19)30424-9.
- A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).Cecchini M, Kortmansky J, Lacy J, Fischbach N, Thumar J, Sabbath K, Gomez C, Sporn J, Stein S, Hochster H. A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2019, 37: 630-630. DOI: 10.1200/jco.2019.37.4_suppl.630.
- Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT.Cecchini M, Miccio J, Pahade J, Lacy J, Salem R, Johnson S, Stein S, Kortmansky J, Johung K. Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT. Journal Of Clinical Oncology 2019, 37: 437-437. DOI: 10.1200/jco.2019.37.4_suppl.437.
- Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).Catenacci D, Lim K, Uronis H, Kang Y, Ng M, Gold P, Enzinger P, Lee K, Lacy J, Park H, Yen J, Odegaard J, Franovic A, Baughman J, Wynter-Horton A, Chen F, Moore P, Wu T, Davidson-Moncada J, Bang Y. Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC). Journal Of Clinical Oncology 2019, 37: 65-65. DOI: 10.1200/jco.2019.37.4_suppl.65.
- 529P Survival of stage IV colorectal cancer: Interaction of cancer location, microsatellite instability and KRAS mutationUhlig J, Stein S, Lacy J, Fuchs C, Kim H. 529P Survival of stage IV colorectal cancer: Interaction of cancer location, microsatellite instability and KRAS mutation Annals Of Oncology 2018, 29: viii177. DOI: 10.1093/annonc/mdy281.075.
- 662P Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)Catenacci D, Park H, Uronis H, Kang Y, Ng M, Gold P, Lacy J, Enzinger P, Park S, Lee K, Yen J, Odegaard J, Franovic A, Baughman J, Muth J, Wynter-Horton A, Wu T, Wigginton J, Davidson-Moncada J, Bang Y. 662P Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA) Annals Of Oncology 2018, 29: viii223. DOI: 10.1093/annonc/mdy282.046.
- P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancerJohung K, Kann B, Lacy J, Stein S, Kortmansky J, Zaheer W, Cheng Y, Lam W, Liu S, Decker R, Hochster H, Higgins S. P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer Annals Of Oncology 2018, 29: v90. DOI: 10.1093/annonc/mdy151.319.
- O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A, ECOG-ACRIN. O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208 Annals Of Oncology 2018, 29: v110. DOI: 10.1093/annonc/mdy149.029.
- NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.Cecchini M, LoRusso P, Shyr Y, Ivy S, Sklar J, Dooley K, Lacy J. NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal Of Clinical Oncology 2018, 36: tps4137-tps4137. DOI: 10.1200/jco.2018.36.15_suppl.tps4137.
- Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.Shitara K, Shah M, Di Bartolomeo M, Lonardi S, Al-Batran S, Van Cutsem E, Ilson D, Chau I, Alsina M, Lacy J, Takahari D, Sugimoto N, Bendell J, Wainberg Z, Tehfe M, Ferry D, Wei R, Walgren R, Das M, Fuchs C. Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. Journal Of Clinical Oncology 2018, 36: 4044-4044. DOI: 10.1200/jco.2018.36.15_suppl.4044.
- Combination of local ablation and chemotherapy for intrahepatic cholangiocarcinoma: Survival trends from the National Cancer Database.Uhlig J, Sellers C, Stein S, Lacy J, "Kevin" Kim H. Combination of local ablation and chemotherapy for intrahepatic cholangiocarcinoma: Survival trends from the National Cancer Database. Journal Of Clinical Oncology 2018, 36: e16150-e16150. DOI: 10.1200/jco.2018.36.15_suppl.e16150.
- Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).Catenacci D, Park H, Uronis H, Kang Y, Lacy J, Enzinger P, Park S, Lee K, Ng M, Gold P, Yen J, Franovic A, Kelly R, Wynter-Horton A, Li D, Muth J, Baughman J, Hong S, Davidson-Moncada J, Bang Y. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). Journal Of Clinical Oncology 2018, 36: 4030-4030. DOI: 10.1200/jco.2018.36.15_suppl.4030.
- Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.Janssen Q, Buettner S, Suker M, Margonis G, Paniccia A, El-Rayes B, Bahary N, Chau I, Hosein P, Ko A, Lacy J, Jamieson N, Tinchon C, Kim K, Besselink M, Wilmink J, Homs M, van Eijck C, Katz M, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. Journal Of Clinical Oncology 2018, 36: e16207-e16207. DOI: 10.1200/jco.2018.36.15_suppl.e16207.
- MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.Oh D, Al-Batran S, Chung H, Hollebecque A, Iqbal S, Kim K, Lacy J, Manji G, O'Reilly E, Rahma O, Yoon H, Kwan A, He X, Barak H, Sayyed P, Zhang X, Wang J, Cha E, Bekaii-Saab T. MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer. Journal Of Clinical Oncology 2018, 36: tps4134-tps4134. DOI: 10.1200/jco.2018.36.15_suppl.tps4134.
- 3:00 PM Abstract No. 261 Radioembolization is cost effective in intrahepatic cholangiocarcinoma: a SEER-Medicare population studyGhodadra A, Raja J, Stein S, Lacy J, Kim H. 3:00 PM Abstract No. 261 Radioembolization is cost effective in intrahepatic cholangiocarcinoma: a SEER-Medicare population study Journal Of Vascular And Interventional Radiology 2018, 29: s113. DOI: 10.1016/j.jvir.2018.01.292.
- 3:09 PM Abstract No. 323 Locoregional therapy and systemic chemotherapy versus systemic chemotherapy on outcome for intrahepatic cholangiocarcinomaSellers C, Ludwig J, Uhlig J, Stein S, Lacy J, Kim H. 3:09 PM Abstract No. 323 Locoregional therapy and systemic chemotherapy versus systemic chemotherapy on outcome for intrahepatic cholangiocarcinoma Journal Of Vascular And Interventional Radiology 2018, 29: s139. DOI: 10.1016/j.jvir.2018.01.359.
- A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).Ramanathan R, McDonough S, Philip P, Hingorani S, Lacy J, Kortmansky J, Thumar J, Chiorean E, Shields A, Behl D, Mehan P, Gaur R, Seery T, Guthrie K, Hochster H. A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). Journal Of Clinical Oncology 2018, 36: 208-208. DOI: 10.1200/jco.2018.36.4_suppl.208.
- RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.Fuchs C, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran S, Van Cutsem E, Ilson D, Tabernero J, Chau I, Ducreux M, Mendez G, Molina Alavez A, Takahari D, Mansoor W, Lacy J, Gorbunova V, Ferry D, Lin J, Das M, Shah M. RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. Journal Of Clinical Oncology 2018, 36: 5-5. DOI: 10.1200/jco.2018.36.4_suppl.5.
- The effect of socioeconomic factors on the outcome of intrahepatic cholangiocarcinoma.Sellers C, Ludwig J, Uhlig J, Stein S, Lacy J, Kim H. The effect of socioeconomic factors on the outcome of intrahepatic cholangiocarcinoma. Journal Of Clinical Oncology 2018, 36: 465-465. DOI: 10.1200/jco.2018.36.4_suppl.465.
- Phase II LAPACT trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).Hammel P, Lacy J, Portales F, Sobrero A, Pazo Cid R, Manzano Mozo J, Terrebonne E, Dowden S, Shiansong Li J, Ong T, Nydam T, Philip P. Phase II LAPACT trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). Journal Of Clinical Oncology 2018, 36: 204-204. DOI: 10.1200/jco.2018.36.4_suppl.204.
- Curtis SA, Curtis BR, Lee AI, Hendrickson JE, Lacy J, Podoltsev NA. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia Hematology 2017, 23: 429-432. PMID: 29281948, DOI: 10.1080/10245332.2017.1419600.
- 730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)Portales F, Philip P, Hammel P, Buscaglia M, Pazo-Cid R, Mozo J, Kim E, Dowden S, Zakari A, Borg C, Terrebonne E, Herrero F, Li J, Ong T, Nydam T, Lacy J. 730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC) Annals Of Oncology 2017, 28: v248-v249. DOI: 10.1093/annonc/mdx369.114.
- Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC).Cecchini M, Salem R, Zaheer Kidwai W, Kortmansky J, Fischbach N, Patel A, Hochster H, Lacy J. Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC). Journal Of Clinical Oncology 2017, 35: 393-393. DOI: 10.1200/jco.2017.35.4_suppl.393.
- Interim results of a multicenter phase II trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).Lacy J, Portales F, Hammel P, Pazo Cid R, Manzano Mozo J, Kim E, Dowden S, Borg C, Sastre J, Bathini V, Terrebonne E, Lopez-Trabada D, Rivera F, Asselah J, Damiani A, Hwang J, Ong T, Nydam T, Shiansong Li J, Philip P. Interim results of a multicenter phase II trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). Journal Of Clinical Oncology 2017, 35: 358-358. DOI: 10.1200/jco.2017.35.4_suppl.358.
- Factors Influencing Hematology Career Choice in Hematology and Oncology Fellows at a Major Academic InstitutionWallace N, Hafler J, Hurwitz M, Podoltsev N, Lacy J, Lee A. Factors Influencing Hematology Career Choice in Hematology and Oncology Fellows at a Major Academic Institution Blood 2016, 128: 3538-3538. DOI: 10.1182/blood.v128.22.3538.3538.
- A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer.Suker M, Beumer B, Sadot E, Marthey L, Faris J, Mellon E, El-Rayes B, Wang-Gillam A, Lacy J, Hosein P, Moorcraft S, Conroy T, Hohla F, Allen P, Taieb J, Hong T, Shridhar R, Chau I, van Eijck C, Koerkamp B. A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer. Pancreatology 2016, 16: s106-s107. DOI: 10.1016/j.pan.2016.05.358.
- Ambulatory redesign: Strategies for quality improvement in patient care.Sinanis N, Lyons C, Smith N, McGlennon M, Parker T, Truini C, Major-Campos M, Lacy J, Michaels K, Dest V, Lisitano R, Adelson K, Lilenbaum R. Ambulatory redesign: Strategies for quality improvement in patient care. Journal Of Clinical Oncology 2016, 34: 85-85. DOI: 10.1200/jco.2016.34.7_suppl.85.
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.Stein S, James E, Cong X, Deng Y, Salem R, Cha C, Chang B, Hochster H, Doddamane I, Boustani A, Patel V, Kortmansky J, Li J, Staugaard C, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Journal Of Clinical Oncology 2016, 34: 395-395. DOI: 10.1200/jco.2016.34.4_suppl.395.
- The Yale Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants of pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy.Gould Rothberg B, Deminie C, Lazowski H, Gibson J, Cha C, Lacy J, Hochster H, Salem R. The Yale Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants of pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy. Journal Of Clinical Oncology 2015, 33: 272-272. DOI: 10.1200/jco.2015.33.3_suppl.272.
- Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.
- Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).James E, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky J, Fischbach N, Chang B, Salem R, Cha C, Stein S, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: e15226-e15226. DOI: 10.1200/jco.2014.32.15_suppl.e15226.
- Measurement of circulating tumor DNA as a cancer biomarker in gastrointestinal malignancies using a novel next-generation sequencing method.James E, James E, Narayan A, Narayan A, Stein S, Lacy J, Patel A, Hochster H, Hochster H. Measurement of circulating tumor DNA as a cancer biomarker in gastrointestinal malignancies using a novel next-generation sequencing method. Journal Of Clinical Oncology 2014, 32: 217-217. DOI: 10.1200/jco.2014.32.3_suppl.217.
- Induction FOLFIRINOX Prior to Chemoradiation for Borderline or Locally-Advanced Pancreatic CancerMancini B, Lloyd S, Lacy J, Rutter C, Chang B. Induction FOLFIRINOX Prior to Chemoradiation for Borderline or Locally-Advanced Pancreatic Cancer International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s304. DOI: 10.1016/j.ijrobp.2013.06.798.
- Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Lacy J. Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: e14534-e14534. DOI: 10.1200/jco.2012.30.15_suppl.e14534.
- Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience.Smyth E, Enzinger P, Li J, Vincitore M, Lacy J, El-Rayes B, Kunz P, Ford J, Robinson E, Kelsen D, Shah M. Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. Journal Of Clinical Oncology 2011, 29: 4056-4056. DOI: 10.1200/jco.2011.29.15_suppl.4056.
- Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma.Li J, Kortmansky J, Saif M, Fischbach N, Ravage-Mass L, Elligers K, Hahn C, Cohenuram M, Lacy J. Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma. Journal Of Clinical Oncology 2010, 28: tps203-tps203. DOI: 10.1200/jco.2010.28.15_suppl.tps203.
- Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastasesArciero C, Salem R, Lacy J, Sigurdson E, Hoffman J, Watson J, Joseph N, Cooper H, Meropol N, Burtness B. Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases Journal Of Clinical Oncology 2006, 24: 13523-13523. DOI: 10.1200/jco.2006.24.18_suppl.13523.
- Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancerBurtness B, Sipples R, Mirto G, Thomas L, Rahman Z, Kloss R, Murren J, Lacy J. Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer Journal Of Clinical Oncology 2004, 22: 4116-4116. DOI: 10.1200/jco.2004.22.14_suppl.4116.
- Guinness M, Kenney J, Reiss M, Lacy J. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Research 2000, 60: 5354-8. PMID: 11034070.
- Kenney J, Guinness M, Curiel T, Lacy J. Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998, 92: 1721-7. PMID: 9716601, DOI: 10.1182/blood.v92.5.1721.417a08_1721_1727.
- Shieh B, Schultz J, Guinness M, Lacy J. Regulation of the human IgE receptor (Fc epsilonRII/CD23) by Epstein-Barr virus (EBV): Ku autoantigen binds specifically to an EBV-responsive enhancer of CD23. International Immunology 1997, 9: 1885-1895. PMID: 9466316, DOI: 10.1093/intimm/9.12.1885.
- Salloum E, Cooper D, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Journal Of Clinical Oncology 1996, 14: 1943-9. PMID: 8656264, DOI: 10.1200/jco.1996.14.6.1943.
- Roth G, Curiel T, Lacy J. Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 1994, 84: 582-7. PMID: 8025284, DOI: 10.1182/blood.v84.2.582.bloodjournal842582.
Biography
Jill Lacy, MD, is a medical oncologist who specializes in gastrointestinal (GI) cancers, including pancreatic and colorectal cancers.
Dr. Lacy works with patients using chemotherapy (which destroys cancer cells with chemicals), immunotherapy (which uses drugs to harness the immune system to fight cancer), and targeted therapy (which targets proteins that control how cancer cells behave).
An active researcher, Dr. Lacy has published studies examining the outcomes of targeted therapy and GI cancers, including potentially harmful side effects, and different treatments for metastatic pancreatic cancer.
In 2020, Dr. Lacy was one of five physicians receiving a Yale Medicine Distinguished Clinical Career Award. The award highlights doctors whose careers demonstrate significant accomplishments and dedication.
Titles
- Professor of Medicine (Medical Oncology)
Education & Training
- FellowYale University School of Medicine (1985)
- ResidentYale University School of Medicine (1982)
- MDYale University (1978)
Additional Information
- Fellow: American Society of Clinical Oncology (2021)
- America's Top Doctors (digital guide): 2016, 2017, 2018, 2019, 2020, 2021: Castle Connolly (2021)
- Exceptional Women In Medicine: Castle Connolly (2019)
- Top Doctors for Cancer, Newsweek Magazine July 2015: (2015)
- Castle Connolly America's Top Doctors for Cancer (digital guide): 2016, 2017, 2018, 2019, 2020, 2021: (2015)
- Member, ASCO Oncology Training Programs Committee, 2007-2010: American Society of Clinical Oncology
- Member, ASCO Diversity in Oncology Initiative Advisory and Review Comm, 2008-present: American Society of Clinical Oncology
- Chairwoman, ASCO Diversity in Oncology Initiative Advisory and Review Comm, 2011, 2012: American Society of Clinical Oncology
- New York Magazine Top Doctor (Medical Oncology), 2006-2008 :
- AB of Internal Medicine, Medical Oncology (1993, recertified: 2015)
- AB of Internal Medicine, Internal Medicine (1982)
- Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ)Cecchini M, Chao J, Shyr Y, Cleary J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Hsu C, Stein S, Thumar J, Kortmansky J, Kunstman J, LoRusso P, Ivy P, Lacy J. Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ) Cancer Research 2022, 82: ct170-ct170. DOI: 10.1158/1538-7445.am2022-ct170.
- Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Cecchini M, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Eder J, Zhang J, Ross J. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. Journal Of Clinical Oncology 2022, 40: 3535-3535. DOI: 10.1200/jco.2022.40.16_suppl.3535.
- Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).Philip P, Bahary N, Mahipal A, Kasi A, Rocha Lima C, Alistar A, Oberstein P, Golan T, Sahai V, Metges J, Lacy J, Fountzilas C, Lopez C, Ducreux M, Hammel P, Salem M, Bajor D, Benson A, Buyse M, Van Cutsem E. Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500). Journal Of Clinical Oncology 2022, 40: 4023-4023. DOI: 10.1200/jco.2022.40.16_suppl.4023.
- Wang JD, Sebastian C, Walther Z, Suresh T, Lacy J, Zhang X, Jain D. An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach. Archives Of Pathology & Laboratory Medicine 2022 PMID: 35512224, DOI: 10.5858/arpa.2021-0457-oa.
- Grant MJ, Finberg KE, Walther Z, Stein SM, Lacy J, Eder JP, Goldberg SB. Yale Precision Medicine Tumor Board: reawakening the guardian of the genome The Lancet Oncology 2022, 23: 337-338. PMID: 35240081, DOI: 10.1016/s1470-2045(22)00037-7.
- Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2022, 20: 167-192. PMID: 35130500, DOI: 10.6004/jnccn.2022.0008.
- Patel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, DOI: 10.21037/jgo-21-202.
- Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal CancerPeters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
- Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients.Uhlig J, Stein S, Lacy J, Cecchini M, Kim K. Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients. Journal Of Clinical Oncology 2021, 39: 462-462. DOI: 10.1200/jco.2021.39.3_suppl.462.
- 259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRCManji G, Bahary N, Chung V, Dalenc F, Ducreux M, Gomez-Roca C, Im S, Kortmansky J, Lacy J, Segal N, Tredan O, Cirovic O, DuPree K, Lenain C, Lu D, Robert L, Xu J, Zhang X, Kim S. 259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC 2020, a157-a158. DOI: 10.1136/jitc-2020-sitc2020.0259.
- Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database AnalysisMiccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.
- The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic CancerMiccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.
- Microsatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database.Uhlig J, Cecchini M, Stein S, Lacy J, Kim K. Microsatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: e16052-e16052. DOI: 10.1200/jco.2020.38.15_suppl.e16052.
- Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).Ko A, Lee J, ALSINA M, Ajani J, Bang Y, Chung H, Lacy J, Lopez C, Oh D, O'Reilly E, Siveke J, Allen S, Al-Sakaff N, Barak H, Lau J, Li S, Retiere A, Shemesh C, Zhang X, Kim K. Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). Journal Of Clinical Oncology 2020, 38: 4540-4540. DOI: 10.1200/jco.2020.38.15_suppl.4540.
- Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study.Patel T, Miccio J, Srikumar T, Prsic E, Adelson K, Kozhevnikov D, Patel K, Lacy J, Cecchini M. Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study. Journal Of Clinical Oncology 2020, 38: 770-770. DOI: 10.1200/jco.2020.38.4_suppl.770.
- Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System.Patel T, Srikumar T, Miccio J, Lacy J, Stein S, Kortmansky J, Staugaard C, Gambaccini M, Axtmayer A, Cecchini M. Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System. Journal Of Clinical Oncology 2020, 38: 769-769. DOI: 10.1200/jco.2020.38.4_suppl.769.
- Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database.Uhlig J, Nie J, Stein S, Cecchini M, Lacy J, Kim H. Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 609-609. DOI: 10.1200/jco.2020.38.4_suppl.609.
- HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).Tempero M, Van Cutsem E, Sigal D, Oh D, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar A, Bates S, Li C, De La Fouchardiere C, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Bullock A. HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). Journal Of Clinical Oncology 2020, 38: 638-638. DOI: 10.1200/jco.2020.38.4_suppl.638.
- Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).Oh D, Ajani J, Bang Y, Chung H, Lacy J, Lee J, Macarulla T, Manji G, O'Reilly E, Allen S, Al-Sakaff N, Barak H, Patel J, Pintoffl J, Shemesh C, Zhang W, Zhang X, Chau I. Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). Journal Of Clinical Oncology 2020, 38: 712-712. DOI: 10.1200/jco.2020.38.4_suppl.712.
- Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysisBuettner S, Janssen Q, Suker M, Beumer B, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali M, Besselink M, Boone B, Chau I, Clarke S, Dillhoff M, El-Rayes B, Frakes J, Grose D, Hosein P, Jamieson N, Javed A, Khan K, Kim K, Kim S, Kim S, Ko A, Lacy J, Margonis G, McCarter M, McKay C, Mellon E, Moorcraft S. Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis Hepato Pancreato Biliary 2020, 22: s327. DOI: 10.1016/j.hpb.2020.04.310.
- 1188PD Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysisCatenacci D, Park H, Uronis H, Kang Y, Ng M, Enzinger P, Lee K, Lim K, Gold P, Lacy J, Park S, Huber K, Wynter-Horton A, Nordstrom J, Wu T, Wigginton J, Baughman J, Rosales M, Davidson-Moncada J, Bang Y. 1188PD Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis Annals Of Oncology 2019, 30: v484-v485. DOI: 10.1093/annonc/mdz253.014.
- KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US.Uhlig J, Stein S, Lacy J, Kim H. KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US. Journal Of Clinical Oncology 2019, 37: e15138-e15138. DOI: 10.1200/jco.2019.37.15_suppl.e15138.
- OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative RadiationMiccio J, Cecchini M, Pahade J, Lacy J, Salem R, Johnson S, Blakaj A, Stein S, Kortmansky J, Johung K. OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative Radiation International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e10-e11. DOI: 10.1016/s0360-3016(19)30424-9.
- A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).Cecchini M, Kortmansky J, Lacy J, Fischbach N, Thumar J, Sabbath K, Gomez C, Sporn J, Stein S, Hochster H. A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2019, 37: 630-630. DOI: 10.1200/jco.2019.37.4_suppl.630.
- Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT.Cecchini M, Miccio J, Pahade J, Lacy J, Salem R, Johnson S, Stein S, Kortmansky J, Johung K. Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT. Journal Of Clinical Oncology 2019, 37: 437-437. DOI: 10.1200/jco.2019.37.4_suppl.437.
- Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).Catenacci D, Lim K, Uronis H, Kang Y, Ng M, Gold P, Enzinger P, Lee K, Lacy J, Park H, Yen J, Odegaard J, Franovic A, Baughman J, Wynter-Horton A, Chen F, Moore P, Wu T, Davidson-Moncada J, Bang Y. Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC). Journal Of Clinical Oncology 2019, 37: 65-65. DOI: 10.1200/jco.2019.37.4_suppl.65.
- 529P Survival of stage IV colorectal cancer: Interaction of cancer location, microsatellite instability and KRAS mutationUhlig J, Stein S, Lacy J, Fuchs C, Kim H. 529P Survival of stage IV colorectal cancer: Interaction of cancer location, microsatellite instability and KRAS mutation Annals Of Oncology 2018, 29: viii177. DOI: 10.1093/annonc/mdy281.075.
- 662P Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)Catenacci D, Park H, Uronis H, Kang Y, Ng M, Gold P, Lacy J, Enzinger P, Park S, Lee K, Yen J, Odegaard J, Franovic A, Baughman J, Muth J, Wynter-Horton A, Wu T, Wigginton J, Davidson-Moncada J, Bang Y. 662P Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA) Annals Of Oncology 2018, 29: viii223. DOI: 10.1093/annonc/mdy282.046.
- P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancerJohung K, Kann B, Lacy J, Stein S, Kortmansky J, Zaheer W, Cheng Y, Lam W, Liu S, Decker R, Hochster H, Higgins S. P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer Annals Of Oncology 2018, 29: v90. DOI: 10.1093/annonc/mdy151.319.
- O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A, ECOG-ACRIN. O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208 Annals Of Oncology 2018, 29: v110. DOI: 10.1093/annonc/mdy149.029.
- NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.Cecchini M, LoRusso P, Shyr Y, Ivy S, Sklar J, Dooley K, Lacy J. NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal Of Clinical Oncology 2018, 36: tps4137-tps4137. DOI: 10.1200/jco.2018.36.15_suppl.tps4137.
- Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.Shitara K, Shah M, Di Bartolomeo M, Lonardi S, Al-Batran S, Van Cutsem E, Ilson D, Chau I, Alsina M, Lacy J, Takahari D, Sugimoto N, Bendell J, Wainberg Z, Tehfe M, Ferry D, Wei R, Walgren R, Das M, Fuchs C. Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. Journal Of Clinical Oncology 2018, 36: 4044-4044. DOI: 10.1200/jco.2018.36.15_suppl.4044.
- Combination of local ablation and chemotherapy for intrahepatic cholangiocarcinoma: Survival trends from the National Cancer Database.Uhlig J, Sellers C, Stein S, Lacy J, "Kevin" Kim H. Combination of local ablation and chemotherapy for intrahepatic cholangiocarcinoma: Survival trends from the National Cancer Database. Journal Of Clinical Oncology 2018, 36: e16150-e16150. DOI: 10.1200/jco.2018.36.15_suppl.e16150.
- Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).Catenacci D, Park H, Uronis H, Kang Y, Lacy J, Enzinger P, Park S, Lee K, Ng M, Gold P, Yen J, Franovic A, Kelly R, Wynter-Horton A, Li D, Muth J, Baughman J, Hong S, Davidson-Moncada J, Bang Y. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). Journal Of Clinical Oncology 2018, 36: 4030-4030. DOI: 10.1200/jco.2018.36.15_suppl.4030.
- Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.Janssen Q, Buettner S, Suker M, Margonis G, Paniccia A, El-Rayes B, Bahary N, Chau I, Hosein P, Ko A, Lacy J, Jamieson N, Tinchon C, Kim K, Besselink M, Wilmink J, Homs M, van Eijck C, Katz M, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. Journal Of Clinical Oncology 2018, 36: e16207-e16207. DOI: 10.1200/jco.2018.36.15_suppl.e16207.
- MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.Oh D, Al-Batran S, Chung H, Hollebecque A, Iqbal S, Kim K, Lacy J, Manji G, O'Reilly E, Rahma O, Yoon H, Kwan A, He X, Barak H, Sayyed P, Zhang X, Wang J, Cha E, Bekaii-Saab T. MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer. Journal Of Clinical Oncology 2018, 36: tps4134-tps4134. DOI: 10.1200/jco.2018.36.15_suppl.tps4134.
- 3:00 PM Abstract No. 261 Radioembolization is cost effective in intrahepatic cholangiocarcinoma: a SEER-Medicare population studyGhodadra A, Raja J, Stein S, Lacy J, Kim H. 3:00 PM Abstract No. 261 Radioembolization is cost effective in intrahepatic cholangiocarcinoma: a SEER-Medicare population study Journal Of Vascular And Interventional Radiology 2018, 29: s113. DOI: 10.1016/j.jvir.2018.01.292.
- 3:09 PM Abstract No. 323 Locoregional therapy and systemic chemotherapy versus systemic chemotherapy on outcome for intrahepatic cholangiocarcinomaSellers C, Ludwig J, Uhlig J, Stein S, Lacy J, Kim H. 3:09 PM Abstract No. 323 Locoregional therapy and systemic chemotherapy versus systemic chemotherapy on outcome for intrahepatic cholangiocarcinoma Journal Of Vascular And Interventional Radiology 2018, 29: s139. DOI: 10.1016/j.jvir.2018.01.359.
- A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).Ramanathan R, McDonough S, Philip P, Hingorani S, Lacy J, Kortmansky J, Thumar J, Chiorean E, Shields A, Behl D, Mehan P, Gaur R, Seery T, Guthrie K, Hochster H. A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). Journal Of Clinical Oncology 2018, 36: 208-208. DOI: 10.1200/jco.2018.36.4_suppl.208.
- RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.Fuchs C, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran S, Van Cutsem E, Ilson D, Tabernero J, Chau I, Ducreux M, Mendez G, Molina Alavez A, Takahari D, Mansoor W, Lacy J, Gorbunova V, Ferry D, Lin J, Das M, Shah M. RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. Journal Of Clinical Oncology 2018, 36: 5-5. DOI: 10.1200/jco.2018.36.4_suppl.5.
- The effect of socioeconomic factors on the outcome of intrahepatic cholangiocarcinoma.Sellers C, Ludwig J, Uhlig J, Stein S, Lacy J, Kim H. The effect of socioeconomic factors on the outcome of intrahepatic cholangiocarcinoma. Journal Of Clinical Oncology 2018, 36: 465-465. DOI: 10.1200/jco.2018.36.4_suppl.465.
- Phase II LAPACT trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).Hammel P, Lacy J, Portales F, Sobrero A, Pazo Cid R, Manzano Mozo J, Terrebonne E, Dowden S, Shiansong Li J, Ong T, Nydam T, Philip P. Phase II LAPACT trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). Journal Of Clinical Oncology 2018, 36: 204-204. DOI: 10.1200/jco.2018.36.4_suppl.204.
- Curtis SA, Curtis BR, Lee AI, Hendrickson JE, Lacy J, Podoltsev NA. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia Hematology 2017, 23: 429-432. PMID: 29281948, DOI: 10.1080/10245332.2017.1419600.
- 730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)Portales F, Philip P, Hammel P, Buscaglia M, Pazo-Cid R, Mozo J, Kim E, Dowden S, Zakari A, Borg C, Terrebonne E, Herrero F, Li J, Ong T, Nydam T, Lacy J. 730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC) Annals Of Oncology 2017, 28: v248-v249. DOI: 10.1093/annonc/mdx369.114.
- Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC).Cecchini M, Salem R, Zaheer Kidwai W, Kortmansky J, Fischbach N, Patel A, Hochster H, Lacy J. Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC). Journal Of Clinical Oncology 2017, 35: 393-393. DOI: 10.1200/jco.2017.35.4_suppl.393.
- Interim results of a multicenter phase II trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).Lacy J, Portales F, Hammel P, Pazo Cid R, Manzano Mozo J, Kim E, Dowden S, Borg C, Sastre J, Bathini V, Terrebonne E, Lopez-Trabada D, Rivera F, Asselah J, Damiani A, Hwang J, Ong T, Nydam T, Shiansong Li J, Philip P. Interim results of a multicenter phase II trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). Journal Of Clinical Oncology 2017, 35: 358-358. DOI: 10.1200/jco.2017.35.4_suppl.358.
- Factors Influencing Hematology Career Choice in Hematology and Oncology Fellows at a Major Academic InstitutionWallace N, Hafler J, Hurwitz M, Podoltsev N, Lacy J, Lee A. Factors Influencing Hematology Career Choice in Hematology and Oncology Fellows at a Major Academic Institution Blood 2016, 128: 3538-3538. DOI: 10.1182/blood.v128.22.3538.3538.
- A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer.Suker M, Beumer B, Sadot E, Marthey L, Faris J, Mellon E, El-Rayes B, Wang-Gillam A, Lacy J, Hosein P, Moorcraft S, Conroy T, Hohla F, Allen P, Taieb J, Hong T, Shridhar R, Chau I, van Eijck C, Koerkamp B. A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer. Pancreatology 2016, 16: s106-s107. DOI: 10.1016/j.pan.2016.05.358.
- Ambulatory redesign: Strategies for quality improvement in patient care.Sinanis N, Lyons C, Smith N, McGlennon M, Parker T, Truini C, Major-Campos M, Lacy J, Michaels K, Dest V, Lisitano R, Adelson K, Lilenbaum R. Ambulatory redesign: Strategies for quality improvement in patient care. Journal Of Clinical Oncology 2016, 34: 85-85. DOI: 10.1200/jco.2016.34.7_suppl.85.
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.Stein S, James E, Cong X, Deng Y, Salem R, Cha C, Chang B, Hochster H, Doddamane I, Boustani A, Patel V, Kortmansky J, Li J, Staugaard C, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Journal Of Clinical Oncology 2016, 34: 395-395. DOI: 10.1200/jco.2016.34.4_suppl.395.
- The Yale Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants of pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy.Gould Rothberg B, Deminie C, Lazowski H, Gibson J, Cha C, Lacy J, Hochster H, Salem R. The Yale Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants of pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy. Journal Of Clinical Oncology 2015, 33: 272-272. DOI: 10.1200/jco.2015.33.3_suppl.272.
- Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.
- Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).James E, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky J, Fischbach N, Chang B, Salem R, Cha C, Stein S, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: e15226-e15226. DOI: 10.1200/jco.2014.32.15_suppl.e15226.
- Measurement of circulating tumor DNA as a cancer biomarker in gastrointestinal malignancies using a novel next-generation sequencing method.James E, James E, Narayan A, Narayan A, Stein S, Lacy J, Patel A, Hochster H, Hochster H. Measurement of circulating tumor DNA as a cancer biomarker in gastrointestinal malignancies using a novel next-generation sequencing method. Journal Of Clinical Oncology 2014, 32: 217-217. DOI: 10.1200/jco.2014.32.3_suppl.217.
- Induction FOLFIRINOX Prior to Chemoradiation for Borderline or Locally-Advanced Pancreatic CancerMancini B, Lloyd S, Lacy J, Rutter C, Chang B. Induction FOLFIRINOX Prior to Chemoradiation for Borderline or Locally-Advanced Pancreatic Cancer International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s304. DOI: 10.1016/j.ijrobp.2013.06.798.
- Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Lacy J. Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: e14534-e14534. DOI: 10.1200/jco.2012.30.15_suppl.e14534.
- Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience.Smyth E, Enzinger P, Li J, Vincitore M, Lacy J, El-Rayes B, Kunz P, Ford J, Robinson E, Kelsen D, Shah M. Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. Journal Of Clinical Oncology 2011, 29: 4056-4056. DOI: 10.1200/jco.2011.29.15_suppl.4056.
- Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma.Li J, Kortmansky J, Saif M, Fischbach N, Ravage-Mass L, Elligers K, Hahn C, Cohenuram M, Lacy J. Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma. Journal Of Clinical Oncology 2010, 28: tps203-tps203. DOI: 10.1200/jco.2010.28.15_suppl.tps203.
- Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastasesArciero C, Salem R, Lacy J, Sigurdson E, Hoffman J, Watson J, Joseph N, Cooper H, Meropol N, Burtness B. Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases Journal Of Clinical Oncology 2006, 24: 13523-13523. DOI: 10.1200/jco.2006.24.18_suppl.13523.
- Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancerBurtness B, Sipples R, Mirto G, Thomas L, Rahman Z, Kloss R, Murren J, Lacy J. Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer Journal Of Clinical Oncology 2004, 22: 4116-4116. DOI: 10.1200/jco.2004.22.14_suppl.4116.
- Guinness M, Kenney J, Reiss M, Lacy J. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Research 2000, 60: 5354-8. PMID: 11034070.
- Kenney J, Guinness M, Curiel T, Lacy J. Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998, 92: 1721-7. PMID: 9716601, DOI: 10.1182/blood.v92.5.1721.417a08_1721_1727.
- Shieh B, Schultz J, Guinness M, Lacy J. Regulation of the human IgE receptor (Fc epsilonRII/CD23) by Epstein-Barr virus (EBV): Ku autoantigen binds specifically to an EBV-responsive enhancer of CD23. International Immunology 1997, 9: 1885-1895. PMID: 9466316, DOI: 10.1093/intimm/9.12.1885.
- Salloum E, Cooper D, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Journal Of Clinical Oncology 1996, 14: 1943-9. PMID: 8656264, DOI: 10.1200/jco.1996.14.6.1943.
- Roth G, Curiel T, Lacy J. Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 1994, 84: 582-7. PMID: 8025284, DOI: 10.1182/blood.v84.2.582.bloodjournal842582.
- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital Care Center - North Haven6 Devine Street, Fl 1North Haven, CT 06473